Olema Pharmaceuticals, Inc.
NASDAQ:OLMABiotechnology
-$0.26 today
- Market cap
- $618.50M
- Beta
- 2.00
- P/E (TTM)
- -5.1
- EPS (TTM)
- -$1.80
Volume 1.18M
Average 1.27M
OLMA Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Olema Pharmaceuticals, Inc.NASDAQ: OLMA
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 3.8% from a year ago
Cash & equivalents stood at $52.55M at the end of Q1 FY2026, up 3.8% from a year earlier and up 8.8% from the prior quarter. Over 3 fiscal years it compounded at +26.8% a year.
Context
- Cash & equivalents amounted to 9.9% of total assets at the end of Q1 FY2026, down 2.5 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +3.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 48.3M USD
- Year-over-year change
- -65.4%
- 4-year CAGR
- +36.7%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 48.3M | -65.4% |
| FY2024 | 2024-12-31 | 139.48M | +103.5% |
| FY2023 | 2023-12-31 | 68.54M | +189.2% |
| FY2022 | 2022-12-31 | 23.7M | +71.6% |
| FY2021 | 2021-12-31 | 13.81M | — |
Cash & Equivalents vs competitors
How OLMA compares with its peers on the latest reported figures
- OLMA's Mar 2026 cash & equivalents of $52.55M is the highest of the 2 companies compared; the peer median is $36.2M.
- Its year-over-year change of +3.8% is the highest of 2, against a peer median of -42.6%.
- Cash & equivalents amounts to 9.9% of total assets for OLMA, versus a peer median of 18.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $52.55M | +3.8% | +26.8% | 9.9% | |
| Mar 2026 | $36.2M | -42.6% | -27.0% | 18.8% | |
| Peer median (excluding OLMA) | $36.2M | -42.6% | -27.0% | 18.8% | |
Competitors are the stored peer set for OLMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 13.81M | 23.7M | 68.54M | 139.48M | 48.3M |
| Short-term Investments | 273.44M | 180.72M | 193.27M | 294.61M | 457.14M |
| Net Receivables | 130K | 319K | 673K | 2.12M | 4.06M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 1.52M | 1.68M | 366K | 1.59M |
| Total Current Assets | 290.69M | 208.9M | 266.51M | 438.47M | 515.45M |
| Property, Plant & Equipment (Net) | 4.72M | 3.98M | 3.26M | 2.06M | 1.15M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 683K | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 540K | 2.77M | 7.17M | 9.76M | 16.83M |
| Total Non-current Assets | 5.26M | 6.75M | 10.43M | 12.51M | 17.98M |
| Total Assets | 295.95M | 215.65M | 276.95M | 450.98M | 533.43M |
| Account Payables | 23K | 374K | 2.7M | 4.46M | 9.25M |
| Short-term Debt | 0 | 0 | 0 | 1.17M | 1.12M |
| Tax Payables | 88K | 68K | 73K | 41K | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 3.96M | 4.6M | 5.47M | 30.31M | 32.02M |
| Total Current Liabilities | 9.02M | 16.55M | 21.62M | 41.76M | 51.8M |
| Long-term Debt | 0 | 0 | 0 | 0 | 69K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 3M |
| Total Non-current Liabilities | 2.36M | 1.55M | 1.43M | 257K | 3.07M |
| Total Liabilities | 11.38M | 18.1M | 23.05M | 42.02M | 54.87M |
| Common Stock | 3K | 3K | 4K | 6K | 8K |
| Retained Earnings | (104.19M) | (208.98M) | (305.63M) | (435.11M) | (597.56M) |
| Accumulated OCI | (149K) | (1.81M) | 347K | 143K | 621K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 284.57M | 197.55M | 253.9M | 408.96M | 478.56M |
| Total Debt | 3.29M | 2.57M | 2.42M | 1.43M | 1.19M |
| Net Debt | (10.52M) | (21.14M) | (66.12M) | (138.05M) | (47.11M) |
Olema Pharmaceuticals, Inc.
NASDAQ:OLMA
Intrinsic Alpha fair value
Locked
Current Price
$7.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.